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This study evaluated the myocardial contrast effect and 
safety of polygelin colloid solution selectively injected 
into tfJe coronary arteries in 25 patients during two-
dimensional echocardiography. Six patients (group I) 
had selective intracoronary injections of nona~itated and 
19 (group II) ofJIand-agitated polygelin colloid solution. 
Myocardial contrast was seen on two-dimensional echo-
cardiographic cross sections in three patients of group 
I and in all patients of group II; in 16 patients it was 
also seen on M-mode echocardiograms. The coptrast 
effect lasted for 15 to 60 seconds. The intensity of myo-
cardial opacification was not significantly influenced by 
the amount of polygelin colloid solution injected, heart 
rate or cardiac size. The total number of contrast-en-
hanced segments after right and left coronary artery 
injections delineated the entire cross-sectional area in 
any given view. 
The possibility and potential of myocardial perfusion im-
aging by contrast-enhanced echocardiography has been 
demonstrated in animal studies (1-23). When compared 
with radionuclide techniques (24,25), this method has better 
spatial and temporal resolution and allows direct and si-
multaneous assessment of both the perfusion and function 
of the myocardium. Contrast-enhanced computed transmis-
sion tomography (26,27), positron emission tomography 
(28,29) and nuclear magnetic resonarice imaging (30) are 
currently under investigation but their availability will re-
rriain limited and their use expensive. Thus, contrast-en-
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None of the patients developed symptoms during or 
immediately after the injections. One patient had tran-
sient secoJld degree atrioventricular block after a right 
coronary wedge injection, one patient showed a Q~S 
axis shift and two others had transient T wave changes. 
There were no aortic blood pressure changes and no 
significant serum enzyme (creatine kinase [CK], CK-MB 
fraction, glutamic oxaloacetic transaminase) elevation or 
alterations of left ventricular function assessed echocar-
diographically.It is concluded that hand-agitated po-
Iygelin colloid solution is a useful and safe intracoronary 
contrast agent for delineating myocardial perfusion areas 
on two-dimensional eciJocardiography in humans. 
(J Am Coil CardioI1985;6:612-20) 
hanced echqcardiography for myocardial perfusion studies 
in humans would offer many advantages. However, an ef-
ficacious and safe echocardiographic contrast agent for hu-
man myocardial perfusion studies in not yet available. 
Preliminary studies have shown that ultrasonic contrast 
effect maY be obtained by using nongaseous agents in the 
form of collagen (31) or gelatin (32) micropheres. A com-
mercially available agent of this type is 3.5% polygelin 
colloid solution (Haemaccel-Hoechst), which is widely used 
for plasma substitution outside the United States and produces 
excellent contrast effect on peripheral venous injection (33). 
Since the surfactant properties of polygelin colloid solution 
may stabilize microbubbles of air in solution, hand agitption 
of this SOhlfiO!1 may yield better contrast effect. The current 
study was thus designed to evaluate the safety and myo-
cardial contrast effect of both nonagitated and hand-agitated 
polygelin colloid solution after selective intracoronary in-
jection for echo~ardiographic myocardial perfusion imaging 
in humans with nonnal coronary arteries or with moderate 
coronary artery obstruction. 
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Table 1. Clinical Data and Quality of Echocontrast Study in 25 Cases 
Quality of Quality of 
Age (yr) NYHA Cardiac 
RCA-CE LCA-CE 
Case and Sex Diagnoses Class Rhythm M-mode 2D M-mode 2D 
Group I (nonagitated contrast solution) 
I 51F MR 11 SR ++ ++ 
2 54M SB SR 0 0 
3 47M AS,AR 11 SR 0 0 0 + 
4 32F MS,MR,AS 11 SR 0 0 0 0 
5 18F MS,MR,AR 11 AF 0 0 0 0 
6 21M SB SR 0 0 0 0 
Group 11 (agitated contrast solution) 
7 48M SB SR 0 + 
8 43F ASD SR 0 + 0 + 
9 39M SB SR 0 ++ 0 ++ 
10 31F MS,AR 11 SR + ++ + ++ 
II 19F ASD,MVP SR LD ++ ++ ++ 
12 15F PS,PFO 11 SR 0 ++ 0 + 
13 18F PDA SR LD ++ ++ ++ 
14 23F VSD SR + ++ ++ ++ 
15 24F ASD SR + ++ ++ ++ 
16 48F MS,MR,AS,AR 11 SR ++ ++ ++ ++ 
17 20F VSD SR + ++ 0 + 
18 24F MS,AR III SR + ++ 0 + 
19 25F MS III SR 0 + + + 
20 41M SB SR + ++ ++ ++ 
21 17M ASD SR + + + ++ 
22 45M MS,MR,TR III AF + + 0 + 
23 22F MS III SR 0 0 + ++ 
24 50M MS,AS,AR III AF LD 0 + ++ 
25 42F MS,AR III AF + + + + 
AF = atrial fibrillation; AR = aortic regurgitation; AS aortic stenosis; ASD = atrial septal defect; 
CE = contrast echocardiography; F = female; LCA = left coronary artery; LD = left coronary artery 
dominance; M = male; MR = mitral regurgitation; MS = mitral stenosis; MVP = mitral valve prolapse; 
NYHA Class = New York Heart Association functional class: PDA = patent ductus arteriosus; PFO = patent 
foramen ovale; PS = pulmonary stenosis; RCA = right coronary artery; SB = sinus bradycardia; SR = sinus 
rhythm; TR = tricuspid regurgitation; VSD = ventricular septal defect; - = no effect; + = good: + + = 
excellent. 
Methods 
Study patients (Table 1). Twenty-five patients (9 men 
and 16 women), aged 15 to 54 years (mean ± SO 33 ± 
13), were studied. Twelve had rheumatic valvular heart 
disease and eight had congenital heart disease (secundum 
atrial septal defect in four, ventricular septal defect in two, 
pulmonary valve stenosis in one and patent ductus arteriosus 
in one). Five were referred for electrophysiologic studies 
because of symptomatic bradycardia. One patient had severe 
aortic stenosis and angina pectoris. Twelve patients were in 
New York Heart Association functional class I, seven in 
class II and six in class III (Table I). All patients underwent 
right and left coronary arteriography using the Judkins tech-
nique. Twenty-two patients had normal coronary arteries 
and three had coronary artery disease with less than 50% 
narrowing of luminal diameter. A standby temporary pace-
maker electrode was placed in the apex of the right ventricle 
in all except the last seven patients. Intramuscular injections 
were avoided before and up to 48 hours after the study. 
Electrocardiographic and pressure recordings were made 
with a Siemens Mingograf-Siereg Instrument. A Smith-Kline 
Ekoline 21-Ekosector I or Aloka SSO-119 or SSO-720 in-
strument (or both) was used for echocardiographic record-
ings. Serum enzyme levels (creatine kinase [CK], CK-MB 
fraction and glutamic oxaloacetic transaminase) were seri-
ally determined before and up to 48 hours after the echo-
cardiographic contrast studies. 
3.5% Polygelin colloid solution. Commercially avail-
able 3.5% polygelin colloid solution (Haemaccel-Hoechst) 
was used as the echocardiographic contrast agent. The so-
lution is composed of 3.5% degraded gelatin polypeptides 
cross-linked by way of urea bridges, with 145 mmol/liter 
sodium (Na +), 5.1 mmol/liter potassium (K +), 6.25 
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mmollliter calcium (Ca2+), 145 mmollliter chlorine (Cl), 
traces of phosphates and sulfate anions, anionic polypep-
tides up to isotonic point and sterile distilled water. Phys-
icochemical characteristics of the solution are as follows: 
mean molecular weight: 35,000; relative viscosity ( + 35°C): 
l. 7 to 1.8; isoelectric point: pH 4.7 ± 0.3; pH of infusion 
solution: 7.3 ± 0.3; gel point: below + 3°C; oncotic pres-
sure (+ 37°C): 3.432 to 3.824 kPa. The solution is elimi-
nated in unaltered form by the kidneys and intestines with 
a half-time of 2 to 5 hours. It is pyrogen-free, contains no 
preservatives, is not immunogenic and does not impair co-
agulation (34). 
Echocardiographic examination. Echocardiographic 
myocardial perfusion studies were performed after comple-
tion of cardiac catheterization or electrophysiologic studies, 
or both. The protocol was approved by the Research Review 
Committee of the Department of Internal Medicine of the 
University of Indonesia and was performed according to the 
Declaration of Helsinki (revised). The procedure and re-
search nature of the study were explained in detail and 
written consent was obtained from all patients. All patients 
were studied in the left lateral decubitus position. Gain 
settings were adjusted to provide the best image at the initial 
examination and kept constant during left ventricular M-
mode and two-dimensional studies. Two-dimensional echo-
cardiograms of the parasternal long-axis and short-axis view 
at papillary muscle level were recorded. The contrast agent 
was manually injected through the Judkins catheter into the 
right or left coronary arteries after the catheter position was 
verified by injecting a small amount of Renografin-76%. 
Three to four injections of approximately 5 ml of polygelin 
colloid solution were done in each coronary artery during 
two-dimensional echocardiography and an additional three 
to four injections dur~ng M-mode echocardiography. Myo-
cardial contrast effect on both M-mode and two-dimensional 
echocardiograms was seen by an increase of the intensity 
of echoes from the myocardium immediately after the con-
trast injection. In the first six patients (group I) nonagitated 
contrast solution was used. In the remaining 19 patients 
(group II) hand-agitated polygelin colloid solution was in-
jected. Hand agitation was done by rapidly injecting the 
polygelin colloid solution in and out of a small bowl. Great 
care was taken to remove macroscopic air bubbles from the 
syringe before injection. 
Measurements of echo contrast microbubbles. 
Microbubbles generated through hand agitation and their 
persistence after 5 minutes were measured under the mi-
croscope at a magnification of x 450 with the aid of an 
eyepiece net reticle graduated in 3.6 f.L using similar methods 
as described by Feinstein et al. (35). 
Echocardiographic analysis. M-mode echocardio-
graphic measurements were performed according to recent 
recommendations (36). The mean value of three beats of 
left ventricular end-diastolic/end-systolic dimensions and 
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fractional shortening was calculated before, during and after 
each intracoronary polygelin colloid solution injection. Per-
cent interventricular septal thickening and its motion am-
plitude were measured after left coronary artery injection. 
In the presence of a dominant right coronary artery these 
variables were measured from the posterior left ventricular 
wall after right coronary artery injection. For analysis of 
two-dimensional echocardiograms, the left ventricle was 
divided into several segments. In the long-axis view the 
basal and mid-ventricular septum and the basal and mid-
posterior wall segments (and proximal parts of the apex) 
were imaged. In the short-axis view the anterior and inferior 
interventricular septum and the anterolateral and inferopos-
terior segments of the left ventricle were recorded (Fig. 1). 
The appearance, distribution and extent of contrast effect 
within the myocardium, the rate of its disappearance and 
changes in wall motion and thickening were assessed by 
two independent observers and by one observer on two 
separate occasions. Myocardial contrast effect was semi-
quantitatively graded as excellent ( + + ), good (+ ) or no 
effect ( - ). Interobserver disagreement was resolved by con-
sensus on repeat review of the recording. End-diastolic sin-
gle frame recordings at the papillary muscle level were used 
to quantitate the circumferential contrast effect distribution. 
The percent circumferential extent of myocardial opacifi-
cation was determined as described in Figure 1. The method 
is similar to that reported by Kemper et al. (11). Inter- and 
intraobserver variability were tested in all patients who showed 
myocardial contrast effect after both right and left coronary 
artery injections. Validity level reflects the accuracy of the 
Figure 1. Diagram of the cross-sectional views used for analysis 
in this study. On the left is the parasternal long-axis view, divided 
into five anatomic segments: basal septum (I), mid-septum (2), 
apex (3), mid-posterior (4) and basal posterior (5). On the right 
is the short-axis view at the papillary muscle level. It is divided 
into four segments: anterior and inferior septum (2a and 2b), an-
terolateral (4a) and inferolateral (4b). Method for analysis of the 
distribution of contrast effect which may be transmural (depicted 
as dark areas involving the entire wall) or non transmural (in-
volving only part of the wall) is shown on the right panel. Two 
perpendicular coordinates AB and CD are used, of which AB 
separates the septum into two equal segments. The center of the 
cardiac cross section is determined by superimposing a circle over 
the epicardial border. Extent of contrast effect is measured by 
determining the angles between the radii encompassing the per-
fused segments (broken lines). 
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method for delineating the entire myocardial mass showing 
contrast perfusion for both coronary artery injections, 
Monitoring during intracoronary polygelin colloid so-
lution injections. Continuous recordings of the electrocar-
diogram, aortic blood pressure and echocardiogram were 
made before, during and several minutes after the intracor-
onary polygelin colloid solution injections, Serum CK, CK-
MB and glutamic oxaloacetic transaminase (GOT) levels 
were determined just before and at 8 to 12, 24 and 48 hours 
after the contrast study. The patients were encouraged to 
report all symptoms during and after the contrast study and 
underwent repeat clinical and electrocardiographic exami-
nation 10 to 14 days after the contrast study. 
Statistical analysis. The collected data were processed 
by Adds Multivision computer using a statistical package. 
All group data are expressed as mean ± 1 SD. Student's t 
test was used to compare pre- and postinjection measure-
ments. The correlation coefficient and standard error of the 
estimate were also calculated to determine the inter- and 
intraobserver variability. The observed sum of the circum-
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Figure 2. Parasternal long-axis view before (A) 
and after (8) left coronary artery injection of ap-
proximately 5 ml of polygelin colloid solution. The 
interventricular septum (IVS) becomes densely opa-
cified. Note the absence of heart rate and electro-
cardiographic changes. 
ferential contrast effect distribution after right and left coro-
nary artery injection was compared with the expected value 
of 100% using the paired t test. 
Results 
Size and persistence of microbubbles. Microbubble size 
was 12 ± 10 p., (n = 244); 78% of the bubbles persisted 
after 5 minutes. 
Myocardial contrast effect (Table 1). In 22 patients 
who showed myocardial opacification, this was always ob-
served in the distribution of the injected coronary artery. It 
was seen in the basal and mid-anterior interventricular sep-
tum, apical and anterolateral segments after left coronary 
artery injection and in the inferoposterior segment, inferior 
portion of the septum and the posteromedial papillary mus-
cle after injection in a dominant right coronary artery (Fig. 
2). After left coronary artery injection, 3 of the 6 patients 
in group I and all 19 patients in group II (except for Patient 
7, in whom no left coronary artery injection was performed) 
Figure 3. Left coronary artery echo contrast injec-
tion in a patient with a dominant left coronary artery 
system. Contrast enhancement (E) of both the in-
terventricular septum (lVS) and posterior wall (PW) 
is clearly visible. As expected for a left coronary 
injection, the right ventricular free wall shows no 
contrast enhancement. During the injection the in-
strument gain was not changed. M-mode echocar-
diographic variables and the electrocardiogram do 
not change. Spillover of echo contrast material (ar-
row) into left ventricular cavity is noted (see text). 
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showed myocardial contrast effect in the perfused areas on 
two-dimensional echocardiography. On M-mode echocardi-
ography contrast effect was seen in 1 patient of group I and 
in 12 patients of group II. Opacification of the left ventric-
ular inferoposterior wall occurred after injection into a dom-
inant left coronary artery system (Fig. 3). After right coro-
nary artery injections, myocardial opacification was never 
observed in group I. It was present on two-dimensional 
echocardiography in 17 patients and on M-mode echocardi-
ography in lO patients of group II. 
Opacification of the lateral wall was not uniform on the 
two-dimensional echocardiograms in 14 (64%) of 22 pa-
tients after left coronary artery injections and opacification 
of the interior interventricular septum and inferoposterior 
wall occurred in 15 (18 %) of 18 patients after right coronary 
artery injections (Fig. 4). Opacification of the anterior in-
JACC Vol. 6, No.3 
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Figure 4. Parasternal short-axis views at papillary muscle level. 
Panel A, before echo contrast injection; panel B, after right coro-
nary artery contrast injection and panel C, after left coronary artery 
contrast injection. Opacification of the inferior portion of the in-
terventricular septum and inferoposterior wall (panel B) as well 
as the lateral wall (panel C) is not uniform, while the anterior 
interventricular septum is uniformly opacified. 
terventricular septum was always uniform after left coronary 
artery injections. 
The intensity of myocardial opacification did not depend 
on heart rate, cardiac size or the quantity of polygelin colloid 
solution injected. This quantity was not strictly standard-
ized, however. The contrast effect persisted for 15 to 60 
seconds and was longer after hand-agitated injections; it was 
reproducible on repeat injections in all patients. Sixteen 
Table 2. Intra- and Interobserver Correlations for Measuring Percent Circumferential Extent of 
Intramyocardial Contrast Effect in 16 Patients 
RCA-CE (%) LCA-CE (%) Sum of RCA and LCA 
Case no. Obs I Obs la Obs 2 Obs I Obs la Obs 2 Obs I Obs la Obs 2 
8 42 40 41 53 51 54 96 91 95 
9 36 34 32 68 72 70 104 106 102 
10 38 40 37 61 63 64 99 103 101 
II 33 31 30 64 65 67 97 96 97 
12 32 34 35 59 62 61 91 96 96 
\3 32 32 29 68 68 69 100 100 98 
14 33 34 31 61 63 65 94 97 96 
15 39 37 38 51 49 49 90 86 87 
16 40 41 41 60 61 62 100 102 103 
17 38 39 36 65 67 68 103 106 104 
18 40 41 43 66 69 70 106 110 113 
19 36 37 34 62 61 61 98 98 95 
20 42 43 44 59 57 54 101 100 98 
21 41 37 39 58 61 60 99 98 99 
22 43 42 42 57 55 56 100 97 98 
25 41 41 39 57 59 54 98 100 103 
Mean 37.88 37.69 36.94 60.56 61.43 61.50 98.5 99.12 99.06 
± SD 3.78 3.75 4.75 4.90 6.28 6.58 4.30 5.82 5.58 
Obs = observer; la = observer I on a separate occasion; other abbreviations as in Table I. 
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patients had spillover of the contrast material into the left 
ventricular outflow tract, although angiographic aortic re-
gurgitation could be demonstrated in only six of these pa-
tients (Table I, Fig. 3). 
Reproducibility and validity of the study (Table 2). 
There was a 4% rate of both inter- and intraobserver disa-
greement on recognition of myocardial contrast effect on 
M-mode echocardiography; for two-dimensional echocardi-
ography this ratio was 4 and 0%, respectively. 
The interobserver correlations for quantitating the cir-
cumferential distribution of myocardial contrast effect for 
both right and left coronary injection were satisfactory (mean 
difference [d] for right coronary injection = 0.9 ± 2.1 %, 
p > 0.05, r = 0.92, SEE = 2.40; that for left coronary 
injection = 0.9 ± 2.6%, p > 0.05, r = 0.94, SEE = 
3.40). Similar values for reproducibility were obtained for 
the intraobserver correlations (d = 0.2 ± 1.8%, P > 0.05, 
r = 0.89, SEE = 1.58 for the right and d = 0.9 ± 2.1 %, 
p > 0.05, r = 0.96, SEE = 2.81 for the left coronary 
echo contrast studies). 
The sum of percent circumferential extent of contrast 
distribution after right and left coronary injections was not 
significantly different from the expected value of 100% 
whether obtained by observer I (d = 1.5 ± 4.3%, p > 
0.05), observer I on a separate occasion (d = 0.9 ± 5.8%, 
p > 0.05) or observer 2 (d = 0.9 ± 5.6%, p > 0.05) 
(Table 2). 
Side effects. No patient reported adverse effects due to 
the contrast study. Even the patient with severe aortic ste-
nosis and angina pectoris on entry into the study group did 
not develop new symptoms. No symptoms were reported 
in the 2 weeks after the study. 
Electrocardiographic, hemodynamic and enzymatic 
effects (Tables 3 and 4). Heart rate did not change sig-
nificantly during and after left or right coronary artery in-
jections and there was no difference between nonagitated 
and hand-agitated right coronary artery contrast injections . 
One patient with pulmonary stenosis developed a transient 
2: 1 atrioventricular (A V) block after an accidental first right 
coronary artery wedge injection. It disappeared rapidly after 
catheter withdrawal. One patient had a transient QRS axis 
change during both coronary angiography and during the 
echocardiographic contrast injections. Two patients had 
transient negative T waves without ST segment changes. 
No Q wave, ST-T changes or arrhythmias were seen in the 
other patients . 
Left ventricular end-diastolic and end-systolic dimen-
sions, fractional shortening, amplitude of interventricular 
septal and posterior wall motion and thickening did not 
change as a result of hand-agitated or nonagitated polygelin 
colloid solution injections (Table 3). On two-dimensional 
echocardiography, no abnormalities in regional wall motion 
or wall thickening were observed in the segments showing 
contrast effect. Aortic blood pressure did not change during 
618 SANTOSO ET AL. 
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Table 4. Heart Rate and Blood Pressure Changes 
Heart Rate (beats/min) Aortic BP (mm Hg) 
Pre Dr Post Pre Dr Post 
Left coronary artery CE 
Group I 91 :!: 32 88 :!: 31 88 :!: 31 S:130 :!: 15 128 :!: 15 128 :!: 17 
D: 81 :!: 7 80 :!: 5 82 :!: 7 
Group II 81 :!: 15 80 :!: 16 80 :!: 14 S:132 :!: 25 130 :!: 17 133 :!: 25 
D: 79 :!: 10 79 :!: 10 79 :!: 10 
Total 83 :!: 20 80 :!: 20 82 :!: 19 S: 131 :!: 22 131 :!: 21 131 :!: 23 
D: 80:!: 9 79 :!: 9 82 :!: 9 
Right coronary CE 
Group I 89 :!: 33 89 :!: 31 88 :!: 31 S:124 :!: 15 123 :!: 17 125 :!: 13 
D: 83 :!: 6 80 :!: 7 81 :!: 6 
Group II 81 :!: 17 76 :!: 17 80 :!: 15 S:131 :!: 24 129 :!: 23 130 :!: 25 
D: 80 :!: 10 81 :!: 8 80 :!: 9 
Total 83 :!: 20 78 :!: 20 81 :!: 18 S: 130 :!: 23 128 :!: 22 130 :!: 23 
D: 80 :!: 10 81 :!: 8 80 :!: 9 
The differences in group data before, during and after injection did not reach statistical significance (p > 
0.10). BP = blood pressure; CE = contrast echocardiography; D = diastolic; Dr = during contrast injection 
or myocardial opacification; Post = 3 to 5 minutes after contrast injection; Pre = before contrast injection; 
S = systolic. 
non agitated and hand-agitated polygelin colloid solution in-
jections. Details are provided in Table 4. 
Mean serum CK levels were 43 ± 24, 47 ± 23,45 ± 
20 and 46 ± 18 U/liter (normal 10 to 80), before and at 8 
to 12,24 and 48 hours, respectively, after the echo contrast 
study (p > 0,10). Mean serum CK-MB levels did not change 
and no patient had CK elevation. Eight patients had elevated 
serum GOT levels before the echo contrast studies. In seven 
they were caused by chronic liver congestion and in one it 
was associated with a type B chronic hepatitis. Mean serum 
GOT levels were 21 ± 23, 22 ± 26, 24 ± 27 and 23 ± 
27 U/liter (normal up to 12 U/liter), before and at 8 to 12, 
24 and 48 hours, respectively, after the echo contrast study 
(p> 0.10). 
Discussion 
Contrast agents for echocardiographic myocardial 
perfusion imaging. It has been demonstrated in animal 
experiments that contrast-enhanced two-dimensional echo-
cardiography can be used to identify and quantitate regional 
myocardial perfusion defects and infarct areas. The tech-
nique seems to be more accurate than analysis of wall motion 
or wall thickening for detecting myocardial ischemia (or 
infarction, or both) (3-16,19,20). Various contrast agents 
have been used: sonicated or nonsonicated water, saline-
dextrose 50 and 70% (12,17), Renografin (6,7), Renografin-
saline mixture (9,13,16,22,23), indocyanine green dye (9), 
dextran (12), gelatin-encapsulated microbubbles (2,3), car-
bon dioxide (8), hydrogen peroxide (4,5,10,11,14,15), en-
riched blood, perfluorochemical emulsion (19), fluosol-DA 
(20) and SHU-454 (21). Several of these agents yield ex-
cellent contrast effect and a good reproducibility without 
producing significant side effects in animals. Nevertheless, 
none of these agents has been proven safe or efficacious in 
humans. In 1976, Weyman et al. (37) reported on the use 
of intracoronary indocyanine green dye injections to identify 
the left main coronary artery in humans and no adverse 
effects were noted. No attention was paid to the myocardial 
contrast effect, however. In 1982, Yasui et al. (38) dem-
onstrated that intracoronary injection of meglamine diatri-
zoote (Renografin) can produce myocardial opacification on 
two-dimensional echocardiography. However, we could not 
obtain satisfactory and reproducible opacification in most 
cases. Repeated injections of Renografin-76 are also known 
to produce systemic and cardiac toxicity (39). Factors that 
adversely affect cardiac rhythm and contractility during 
intracoronary injection appear to be the hyperosmolarity and 
calcium chelating properties of the agent injected. The anion 
and cation concentrations seem to be the crucial factors in 
the genesis of arrhythmias (39,40). Physicochemical char-
acteristics of 3.5% polygelin colloid solution indicate that 
this agent lacks these negative factors, and its extensive 
clinical use as a plasma substitute further substantiates its 
safety. Because of this and its known properties as an echo-
cardiographic contrast agent (33), it was chosen as a po-
tential agent for echocardiographic myocardial perfusion 
imaging. 
Safety. Animal studies (33) have indicated that intra-
coronary injection of hand-agitated polygelin colloid solu-
tion is safe. Small amounts of gas (carbon dioxide or hy-
drogen peroxide) have been injected into the coronary arteries 
without important side effects on hemodynamics or cardiac 
irritability in experimental animals (4,5,10,11,14-16) and 
in humans (41). In fact, most catheter injections and flushes 
during left heart catheterization and coronary arteriography 
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are not completely air-free yet cause no adverse effects. The 
amount of microbubbles necessary to produce a strong ul-
trasonic contrast effect is quite small (42). Indeed, transient 
coronary occlusions of greater magnitude may be tolerated: 
currently percutaneous coronary angioplasty is performed 
with increasing total duration of episodes of occlusion. In 
a recent report (43), the median interference was 4 minutes 
and in a few cases it exceeded 10 minutes. 
Other than 2: 1 A V block (1 patient), only minor electro-
cardiographic changes were observed (3 patients) in our 
study; the other 21 patients did not have significant clinical, 
electrocardiographic, hemodynamic, enzymatic or echocar-
diographic changes. This finding is consistent with the re-
cent report (44) of the Committee on Contrast Echocardi-
ography of the American Society of Echocardiography that 
the risk of intravenous contrast echocardiography is very 
low. 
Echocardiographic measurements. M-mode echo-
cardiography permits visualization of the contrast effect but 
does not provide spatial information. However, measure-
ment of c~anges of left ventricular cavity dimension, wall 
motion and wall thickening are more accurate and repro-
ducible (45,46) and we therefore decided to use this tech-
nique to asses the effects of polygelin colloid solution on 
left ventricular function. 
Because the coronary circulation is transmurally distrib-
uted (39), it should be possible to estimate perfusion area 
by the circumferential method as described. This method 
has also been proven to be accurate (11,47). In our study 
the small inter- and intraobserver variability for determining 
the percent circumferential extent of the intramyocardial 
contrast effect distribution confirmed the reliability of the 
technique. Validity is reflected by the finding that the sum 
of contrast-enhanced areas seen after both right and left 
coronary injections did not differ significantly from the ex-
pected value of 100%. Some overestimation of the opacified 
area may result from the limited lateral resolution and 
"blooming" effect, an artifact cause by exceeding the dy-
namic range of the display monitor when imaging bright 
structures (48). Because our study was designed to test the 
feasibility and toxicity of intracoronary polygelin colloid 
solution injection in humans, we did not attempt to quan-
titate the contrast effect. Rigid standardization of the injec-
tate and injection technique and the use of digital subtraction 
(15,19,49) or videodensitometric techniques (17,50) may 
provide such a quantitative analysis in the future and in-
crease the amount of information obtained by myocardial 
perfusion imaging. 
Conclusions. Our study indicates that hand-agitated po-
Iygelin colloid solution is a safe and reproducible echocar-
diographic contrast agent for selective intracoronary injec-
tion and myocardial perfusion imaging. It does not induce 
myocardial ischemia or myocardial damage. Further studies 
are needed to prove the applicability of this technique in 
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patients with coronary artery disease. It is anticipated that 
in the future the technique could be performed in conjunction 
with coronary arteriography to assess myocardial perfusion 
and size of ischemic or infarcted areas and during ap.gio-
plasty to assess collateral vessel physiology and angioplasty 
results. 
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ijaya, MD, MPH and TM, PhD for help in microbubbles analysis, Joedo 
Prihartono, MD, MPH for statistical analysis and Tati Hidayat, Tineke 
van der Kolk and Roberta Shaked for secretarial help. 
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